ADAPTIMMUNE THERAPEUTICS PLC (ADAPY) Operating income 2016–2024
ADAPTIMMUNE THERAPEUTICS PLC (ADAPY) annual operating income history from SEC filings — each fiscal year as reported.
-$68.8MFY2024 · since FY2016: -$72.8M → -$68.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -$68.8M | +50.8% |
| FY2023 | -$139.7M | +14.8% |
| FY2022 | -$164.0M | -1.1% |
| FY2021 | -$162.2M | -21.6% |
| FY2020 | -$133.4M | +4.6% |
| FY2019 | -$139.8M | -69.7% |
| FY2018 | -$82.4M | -2.1% |
| FY2017 | -$80.7M | -10.8% |
| FY2016 | -$72.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ADAPY financial trends
ADAPY RevenueADAPY Net incomeADAPY Net marginADAPY Gross profitADAPY Gross marginADAPY Operating marginADAPY Operating cash flowADAPY Free cash flowADAPY Capital expendituresADAPY Return on equityADAPY Stock buybacksADAPY Dividends paidADAPY Total assetsADAPY Total liabilitiesADAPY Shareholders’ equityADAPY overview →